Saturday 17 October 2026
Export BMEA’s income statement to Excel — free account
Biomea Fusion, Inc.
BMEA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 76.5% and free cash flow grew 47.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.03
+3.57%
Follow BMEA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(209.00%) | (152.35%) | (189.44%) | (164.14%) | |
| (115.59%) | (89.23%) | (88.62%) | (59.14%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(280.88%) | (131.20%) | (121.19%) | (125.18%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.44) | (1.35) | (0.78) | (0.65) | |
Free Cash Flow |
(86.43) | (70.37) | (56.15) | (46.91) | |
Capital Expenditures |
— | — | 0.22 | 0.28 | |
| Other line items | |||||
Cash ROIC |
(138.82%) | (82.44%) | (88.04%) | (99.11%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 1.14 | 1.25 | 1.45 | |
Depreciation/Fixed assets |
9.16 | 9.21 | 14.73 | 11.49 | |
Capex/Depreciation |
0.00 | 0.00 | 0.23 | 0.52 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.44) | (1.35) | (0.78) | (0.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates